CRDL – cardiol therapeutics inc. - class a common shares (US:NASDAQ)

News

Trends in the $6 Billion Botanical Drugs Industry, 2030: An Assessment of Emerging Growth Opportunities and Strategic Developments [Yahoo! Finance]
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com